SCHEMBL559249

SCHEMBL559249

C=[C]c1ccc(N(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.58
TSHR P16473 6/20 0.58
ALOX15 P16050 3/20 0.58
HSD17B10 Q99714 3/20 0.58
MAPK1 P28482 5/20 0.46
CYP3A4 P08684 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
TP53 P04637 2/20 0.46
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
SLC2A1 P11166 1/20 0.41
HIF1A Q16665 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2A13 Q16696 1/20 0.41
HPGD P15428 1/20 0.41
CHRM5 P08912 1/20 0.40
CHKA P35790 1/20 0.40
HBB P68871 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770159 0.78 ALDH1A1 (0.65) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL10300053 0.78 ALDH1A1 (0.65) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL547220 0.78 ALDH1A1 (0.65) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL65261 0.76 ALDH1A1 (1.00) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL60385 0.74 ALDH1A1 (0.58) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL194965 0.74 ALDH1A1 (0.58) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL1858216 0.74 ALDH1A1 (0.58) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL186079 0.74 ALDH1A1 (0.58) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL195394 0.74 ALDH1A1 (0.58) ALDH1A1TSHRALOX15HSD17B10MAPK1
SCHEMBL2902079 0.73 ALDH1A1 (0.52) ALDH1A1TSHRMAPK1CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020189390-A1 ADHESIVE AGENT COMPOSITION, ADHESIVE AGENT LAYER, AND ADHESIVE SHEET 日東電工株式会社 2020-09-24 WO disclosed
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9645128-B2 Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity JNC CORPORATION (JP) 2017-05-09 US disclosed
US-20170121755-A1 COELENTERAZINE ANALOGS JNC CORPORATION 2017-05-04 US disclosed
US-9567623-B2 Coelenterazine analogs JNC CORPORATION (JP) 2017-02-14 US disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
US-9346767-B2 Substituted pyrazines and a process for producing the same JNC CORPORATION (JP) 2016-05-24 US disclosed
US-20150344936-A1 COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-12-03 US disclosed
US-9151739-B2 Coelenterazine analogs and manufacturing method thereof JNC CORPORATION (JP) 2015-10-06 US disclosed
EP-1655294-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121755-A1 COELENTERAZINE ANALOGS GLB1, CRY1, GTF3C5 ALDH1A1 1716/4885TSHR 2558/4885ALOX15 3273/4885
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 ALDH1A1 2905/4885TSHR 3923/4885ALOX15 1404/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 ALDH1A1 3101/4885TSHR 3797/4885ALOX15 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.